Multimodal Assessment of Frailty in Acute Stroke Patients
Launched by UNIVERSITY OF GIESSEN · Sep 7, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Multimodal Assessment of Frailty in Acute Stroke Patients," is studying how frailty affects patients who have had a stroke. Frailty can make recovery more difficult and may lead to worse outcomes. The researchers want to find out how common frailty is among stroke patients, what factors contribute to it (like poor nutrition or difficulty moving), and whether frail patients experience more complications or have worse recovery than those who are not frail.
To participate in this study, individuals should be aged 65 or older and have been treated at the stroke unit at the University Hospital Giessen for either an ischemic stroke (which is caused by a blocked blood vessel) or a hemorrhagic stroke (which is caused by bleeding in the brain). Patients who withdraw care within 24 hours after being admitted will not be eligible. Those who join the study can expect to undergo various assessments to evaluate their frailty and understand its impact on their recovery from stroke. This research is important because it could help improve care for frail stroke patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • treated at the certified stroke-unit of the Dpt. of Neurology, University Hospital Giessen
- • diagnosis of ischemic (including transient ischemic attack) or hemorrhagic stroke
- Exclusion Criteria:
- • withdrawal of care within 24 hours after admission
About University Of Giessen
The University of Giessen, a prominent research institution in Germany, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including medicine, pharmacology, and public health, to conduct rigorous studies aimed at improving patient outcomes. Committed to maintaining the highest ethical standards and regulatory compliance, the University of Giessen fosters a research environment that encourages scientific inquiry and the translation of findings into clinical practice, ultimately contributing to the advancement of healthcare and therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gießen, Hesse, Germany
Patients applied
Trial Officials
Stefan Gerner, MD
Principal Investigator
Department of Neurology, University Hospital Giessen/Germany
Thorsten Doeppner, MD
Study Chair
Department of Neurology, University Hospital Giessen/Germany
Hagen Huttner, MD, PhD
Study Chair
Department of Neurology, University Hospital Giessen/Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported